Yes there is still a long way for 520 to go and I am not assuming anything. But, if it pans out and adds meaningfully as part of a combo (be it with kyprolis, pom, or whatever), wouldn't a company have an incentive to utlize it as a combo, as opposed to having a competitor utilize it with a competing drug as part of a superior regimen? Don't understand why there wouldn't be an incentive for the established company to maintain its edge in such a scenario. All hypothetical at this stage, obviously.
I understand what you're saying, but I think the company with the investigational drug is usually the one soliciting the company with the deep pockets / approved drug. I think the tables turn when the company with the investigational drug holds until they have very strong proof-of-concept / high chance of success (I'm thinking INCY, PCYC).
From reading your posts on this topic, I get the feeling that you're turning the balance of power upside-down a little. ARRY doesn't seem to be looking to go the monotherapy route with 520, doesn't appear to be rushing into their own combo trials, nor do they have strong proof-of-concept combo data in hand. I think it's fair to say that they're not the ones holding the upper hand. Apologies if I'm misinterpreting.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.